An Italian-led study published earlier this year reported that androgen deprivation therapy may play a protective role against the risk of SARS-CoV-2 infection. Using an expansive enterprise-wide COVID-19 testing registry, Cleveland Clinic researchers set out to validate this report. Eric Klein, MD, discusses their findings.
Metastatic prostate cancer patients with an adrenal-permissive variant of the HSD3B1 gene are more likely to have aggressive, early castration-resistant disease and shorter survival, a Cleveland Clinic-led study has found. The finding could help physicians identify patients most likely to benefit from escalated treatment.
If therapies for advanced prostate cancer — particularly those with curative intent for oligometastatic disease — are to progress, clinical trials will need to take into account what’s driving tumor progression, what treatment will add benefit, and for which patients, contends eminent cancer researcher Nima Sharifi, MD.
A research team led by noted Cleveland Clinic physician-researcher Nima Sharifi, MD, is honing in on what makes certain men more susceptible to prostate cancer that is likely to progress from hormone-sensitive to castration-resistant.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-related genetic abnormality can help predict individual patient responses to specific prostate cancer therapies.
Cleveland Clinic physician-researcher recognized as a Top Ten Clinical Research Achievement awardee by national organization of senior researchers and thought leaders from leading academic health centers.